Literature DB >> 28004354

Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Henriett Butz1, Kinga Németh2, Dóra Czenke2, István Likó3, Sándor Czirják4, Vladimir Zivkovic5, Kornélia Baghy6, Márta Korbonits7, Ilona Kovalszky6, Péter Igaz2, Károly Rácz8,2, Attila Patócs2,3.   

Abstract

Dysregulation of G1/S checkpoint of cell cycle has been reported in pituitary adenomas. In addition, our previous finding showing that deregulation of Wee1 kinase by microRNAs together with other studies demonstrating alteration of G2/M transition in nonfunctioning pituitary adenomas (NFPAs) suggest that G2/M transition may also be important in pituitary tumorigenesis. To systematically study the expression of members of the G2/M transition in NFPAs and to investigate potential microRNA (miRNA) involvement. Totally, 80 NFPA and 14 normal pituitary (NP) tissues were examined. Expression of 46 genes encoding members of the G2/M transition was profiled on 34 NFPA and 10 NP samples on TaqMan Low Density Array. Expression of CDC25A and two miRNAs targeting CDC25A were validated by individual quantitative real time PCR using TaqMan assays. Protein expression of CDC25A, CDC25C, CDK1 and phospho-CDK1 (Tyr-15) was investigated on tissue microarray and immunohistochemistry. Several genes' expression alteration were observed in NFPA compared to normal tissues by transcription profiling. On protein level CDC25A and both the total and the phospho-CDK1 were overexpressed in adenoma tissues. CDC25A correlated with nuclear localized CDK1 (nCDK1) and with tumor size and nCDK1 with Ki-67 index. Comparing primary vs. recurrent adenomas we found that Ki-67 proliferation index was higher and phospho-CDK1 (inactive form) was downregulated in recurrent tumors compared to primary adenomas. Investigating the potential causes behind CDC25A overexpression we could not find copy number variation at the coding region nor expression alteration of CDC25A regulating transcription factors however CDC25A targeting miRNAs were downregulated in NFPA and negatively correlated with CDC25A expression. Our results suggest that among alterations of G2/M transition of the cell cycle, overexpression of the CDK1 and CDC25A may have a role in the pathogenesis of the NFPA and that CDC25A is potentially regulated by miRNAs.

Entities:  

Keywords:  CDC25A; Cell cycle; G2/M transition; Pituitary adenoma; miRNA

Mesh:

Substances:

Year:  2016        PMID: 28004354     DOI: 10.1007/s12253-016-0163-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  60 in total

Review 1.  CDC25A: a rebel within the CDC25 phosphatases family?

Authors:  Anne Fernandez-Vidal; Anne Mazars; Stéphane Manenti
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

2.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.

Authors:  Katherine A Michaelis; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Michael G Edwards; Mark Geraci; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

3.  The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph.

Authors:  S L Asa; A M Bamberger; B Cao; M Wong; K L Parker; S Ezzat
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

4.  MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.

Authors:  Marek Mraz; Dasa Dolezalova; Karla Plevova; Katerina Stano Kozubik; Veronika Mayerova; Katerina Cerna; Katerina Musilova; Boris Tichy; Sarka Pavlova; Marek Borsky; Jan Verner; Michael Doubek; Yvona Brychtova; Martin Trbusek; Ales Hampl; Jiri Mayer; Sarka Pospisilova
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.

Authors:  Henriett Butz; István Likó; Sándor Czirják; Péter Igaz; Mohammed Munayem Khan; Vladimir Zivkovic; Katalin Bálint; Márta Korbonits; Károly Rácz; Attila Patócs
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

6.  Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.

Authors:  Gérald Raverot; Anne Wierinckx; Emmanuelle Dantony; Carole Auger; Guillaume Chapas; Laurent Villeneuve; Thierry Brue; Dominique Figarella-Branger; Pascal Roy; Emmanuel Jouanneau; Michel Jan; Joël Lachuer; Jacqueline Trouillas
Journal:  J Clin Endocrinol Metab       Date:  2010-02-17       Impact factor: 5.958

Review 7.  The epidemiology and genetics of pituitary adenomas.

Authors:  Adrian F Daly; Maria A Tichomirowa; Albert Beckers
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

8.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

9.  MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.

Authors:  Seung-Ok Lee; Tatyana Masyuk; Patrick Splinter; Jesús M Banales; Anatoliy Masyuk; Angela Stroope; Nicholas Larusso
Journal:  J Clin Invest       Date:  2008-10-23       Impact factor: 14.808

Review 10.  MicroRNAs in Human Pituitary Adenomas.

Authors:  Xu-Hui Li; Elaine Lu Wang; Hai-Meng Zhou; Katsuhiko Yoshimoto; Zhi Rong Qian
Journal:  Int J Endocrinol       Date:  2014-12-08       Impact factor: 3.257

View more
  10 in total

1.  Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.

Authors:  Ashley L B Raghu; Megan C Everson; Ahmed Helal; Satoshi Kiyofuji; Michelle J Clarke; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-01

2.  Diagnostic value of abnormal chromosome 3p genes in small-cell lung cancer.

Authors:  Chunxu Ma; Jihua Zhao; Ying Wu; Jun Wang; Hao Wang
Journal:  Oncol Lett       Date:  2022-05-16       Impact factor: 3.111

Review 3.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

Review 4.  Advancements in the study of miRNA regulation during the cell cycle in human pituitary adenomas.

Authors:  Ting Zhang; Zijiang Yang; Heng Gao
Journal:  J Neurooncol       Date:  2017-06-02       Impact factor: 4.130

5.  The Search of miRNA Related to Invasive Growth of Nonfunctioning Gonadotropic Pituitary Tumors.

Authors:  Joanna Boresowicz; Paulina Kober; Natalia Rusetska; Maria Maksymowicz; Agnieszka Paziewska; Michalina Dąbrowska; Natalia Zeber-Lubecka; Jacek Kunicki; Wiesław Bonicki; Jerzy Ostrowski; Janusz A Siedlecki; Mateusz Bujko
Journal:  Int J Endocrinol       Date:  2020-12-05       Impact factor: 3.257

6.  Knockdown of Annexin-A1 Inhibits Growth, Migration and Invasion of Glioma Cells by Suppressing the PI3K/Akt Signaling Pathway.

Authors:  Liqing Wei; Li Li; Li Liu; Ru Yu; Xing Li; Zhenzhao Luo
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

7.  Tat-NTS Suppresses the Proliferation, Migration and Invasion of Glioblastoma Cells by Inhibiting Annexin-A1 Nuclear Translocation.

Authors:  Zhenzhao Luo; Li Liu; Xing Li; Weiqun Chen; Zhongxin Lu
Journal:  Cell Mol Neurobiol       Date:  2021-08-03       Impact factor: 4.231

8.  Comprehensive analysis of differential expression profiles reveals potential biomarkers associated with the cell cycle and regulated by p53 in human small cell lung cancer.

Authors:  Zhong Ni; Xiting Wang; Tianchen Zhang; Linlin Li; Jianxue Li
Journal:  Exp Ther Med       Date:  2018-02-02       Impact factor: 2.447

9.  Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas.

Authors:  Kinga Németh; Nikolette Szücs; Sándor Czirják; Lilla Reiniger; Borbála Szabó; Gábor Barna; Katalin Karászi; Péter Igaz; Vladimir Zivkovic; Márta Korbonits; Attila Patócs; Henriett Butz
Journal:  Oncotarget       Date:  2018-06-26

Review 10.  MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.

Authors:  Ozal Beylerli; Narasimha M Beeraka; Ilgiz Gareev; Valentin Pavlov; Guang Yang; Yanchao Liang; Gjumrakch Aliev
Journal:  Int J Mol Sci       Date:  2020-10-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.